GSK (GSK) Expected to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

GSK Price Performance

Shares of GSK stock opened at $34.91 on Tuesday. GSK has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50-day moving average price is $34.07 and its two-hundred day moving average price is $37.67. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $72.34 billion, a price-to-earnings ratio of 22.67, a P/E/G ratio of 1.38 and a beta of 0.64.

Analysts Set New Price Targets

Several brokerages recently issued reports on GSK. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.